Pfenex Gives Teriparatide Latest After Setback

As Company Underlines Confidence In Supply Chain

 
• By Dean Rudge

Pfenex has provided an update on its bid to secure a therapeutic equivalence determination for its PF708 teriparatide product in the US, after itself and partner Alvogen were knocked back last month.

FDA_Truck
The FDA has told Pfenex that further information is required for teriparatide • Source: Shutterstock

More from Strategy

More from Business